alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
xml version="1.0" encoding="UTF-8"?


C\_2021301EN.01000601.xml


| | | | |
| --- | --- | --- | --- |
| 28.7.2021 | EN | Official Journal of the European Union | C 301/6 |

---

Prior notification of a concentration

(Case M.10344 — Accenture/Umlaut)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 301/05)

1.

On 20 July 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2021301EN.01000601-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | Accenture plc (‘Accenture’, Ireland), |

| | |
| --- | --- |
| — | Umlaut SE (‘Umlaut’, Germany). |

Accenture acquires, within the meaning of Article 3(1)(b) of the Merger Regulation, sole control of the whole of Umlaut.

The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

| | |
| --- | --- |
| — | for Accenture: global professional services organization providing management consulting, technology, and outsourcing services, |

| | |
| --- | --- |
| — | for Umlaut: German-based professional service provider focusing on the area of engineering services, that is the provision of fulfilment services (such as design, development and optimization of complex products and features) and corresponding consulting services (including strategy, process, organizational and technical consulting), as well as engineering testing and validation services. |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2021301EN.01000601-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10344 — Accenture/Umlaut

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| |
| --- |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2021301EN.01000601-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2021301EN.01000601-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---
#### UNITED STATES of America, Plaintiff-Appellee, v. Richard Allen ADDERSON, Defendant-Appellant.

No. 06-14843

Non-Argument Calendar.

United States Court of Appeals, Eleventh Circuit.

June 14, 2007.

Lennard B. Register, III, Edwin F. Knight, U.S. Attorney’s Office, Pensacola, FL, E. Bryan Wilson, Tallahassee, FL, for Plaintiff-Appellee.

Before TJOFLAT, ANDERSON and HULL, Circuit Judges.

PER CURIAM:

Richard A. Grossman, appointed counsel for Richard Allen Adderson in this direct criminal appeal, has moved to withdraw from further representation of the appellant and filed a brief pursuant to *Anders v. California,*386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967). Our independent review of the entire record reveals that counsel’s assessment of the relative merit of the appeal is correct. Because independent examination of the entire record reveals no arguable issues of merit, counsel’s motion to "withdraw is GRANTED, and *930Adderson’s conviction and sentence are AFFIRMED.
I 

114TH CONGRESS 

1ST SESSION H. R. 2046 

To amend title 38, United States Code, to improve the participation of 

the Department of Veterans Affairs in the prescription drug monitoring 

programs of the States. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 28, 2015 

Mr. DUFFY introduced the following bill; which was referred to the Committee 

on Veterans’ Affairs 

A BILL 

To amend title 38, United States Code, to improve the 

participation of the Department of Veterans Affairs in 

the prescription drug monitoring programs of the States. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Prescription Drug Ac5 countability Act’’. 


Emcdonald on DSK67QTVN1PROD with BILLS
2 

•HR 2046 IH

1 SEC. 2. PARTICIPATION OF DEPARTMENT OF VETERANS 

2 AFFAIRS IN PRESCRIPTION DRUG MONI3 TORING PROGRAMS OF STATES. 

4 Section 7332(b) of title 38, United States Code, is 

5 amended— 

6 (1) in paragraph (2)(G), by striking ‘‘To a 

7 State’’ and inserting ‘‘In accordance with paragraph 

8 (4), to a State’’; and 

9 (2) by adding at the end the following new 

10 paragraph: 

11 ‘‘(4) The Secretary shall participate in each State 

12 controlled substance monitoring program described in 

13 paragraph (2)(G), including by providing to such program 

14 the information of an individual before filling an opiate 

15 prescription for such individual.’’. 

Æ 


Emcdonald on DSK67QTVN1PROD with BILLS
# C_2021509EN.01000501.xml

| 17.12.2021 | EN | Official Journal of the European Union | C 509/5 |
| --- | --- | --- | --- |

17.12.2021

EN

Official Journal of the European Union

C 509/5

---

Non-opposition to a notified concentration

(Case M.10455 – CVC / PANZANI)

(Text with EEA relevance)

(2021/C 509/05)

On 6 December 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10455. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10455. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
biei_ex103





  Exhibit 10.3











 



THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENT


 


This THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENT
(this “First Amendment”)
is made as of the 11th day of May, 2020, by and between Marv
Enterprises, LLC a Limited Liability Company organized and existing
under the laws of the Commonwealth of Pennsylvania
(“Marv”)
with an address of P.O. Box 1332, Hermitage, PA 16148 and Premier
Biomedical, Inc.., a Nevada corporation with its principal business
address at 1362 Springfield Church Road, Jackson Center, PA 16133
(“Licensee”).


 


WHEREAS,
Marv and Licensee have previously entered into an Exclusive License
Agreement with effective date of May 12, 2010;


 


WHEREAS
Marv and Licensee have previously entered into a First Addendum on
August 17, 2011;


 


WHEREAS
Marv and Licensee have previously entered into a Second Addendum on
December 27, 2011; and


 


WHEREAS,
the parties wish to further amend the Agreement as set forth herein
to be consistent with the actions of the parties since the
effective date of the Exclusive License Agreement up to an
including the effective date of this Third Addendum.


 


NOW,
THEREFORE, in consideration of the foregoing and for good and
valuable consideration, the receipt and sufficiency which are
hereby acknowledged, the parties hereby agree as
follows:


 


That
under the Second Addendum 1.(i) and (ii), the Applications listed
in Appendix A current as of the effective date of this agreement,
are not refused by Premier and that Premier will pay Marv for
expenses of all patent work. And that under 1. (iii), Premier will
be the exclusive licensee under and as part of the Original
Agreement.


 


IN
WITNESS WHEREOF, the parties have executed this First Amendment as
of the date first written above.


 


	LICENSEE	
	
	
LICENSOR	

 


	

By        5/11/2020




	

 

	

 

	



By /s/ Mitchell S.
Felder 	

 


	William
Hartman	

 

	

 

	
Mitchell S.
Felder 


	

 


	
CEO and President
of Premier Biomedical,
Inc.  

	

 

	

 

	Marv Enterprises,
LLC
# C_2021472EN.01001401.xml

| 23.11.2021 | EN | Official Journal of the European Union | C 472/14 |
| --- | --- | --- | --- |

23.11.2021

EN

Official Journal of the European Union

C 472/14

---

Prior notification of a concentration

(Case M.10465 – Adecco/AKKA)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 472/11)

1.

This notification concerns the following undertakings:

| — | Adecco Group AG (‘Adecco’, Switzerland), |
| --- | --- |

—

Adecco Group AG (‘Adecco’, Switzerland),

| — | AKKA Technologies SE (‘AKKA’, Belgium). |
| --- | --- |

—

AKKA Technologies SE (‘AKKA’, Belgium).

Adecco acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of AKKA. The concentration is accomplished by way of purchase of shares.

2.

| — | for Adecco: provision of human capital solutions including flexible placement, permanent placement, career transition, HR outsourcing, consulting, training, and other HR services on a global basis. Through its subsidiary Modis, Adecco is also active in the provision of IT and digital-engineering services, |
| --- | --- |

—

for Adecco: provision of human capital solutions including flexible placement, permanent placement, career transition, HR outsourcing, consulting, training, and other HR services on a global basis. Through its subsidiary Modis, Adecco is also active in the provision of IT and digital-engineering services,

| — | for AKKA: provision of engineering and research and development consulting services. AKKA undertakes its activities mainly in the EEA, however has been expanding on a global basis, in particular in North America. |
| --- | --- |

—

for AKKA: provision of engineering and research and development consulting services. AKKA undertakes its activities mainly in the EEA, however has been expanding on a global basis, in particular in North America.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10465 – Adecco/AKKA

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---
# C_2021021EN.01000201.xml

| 20.1.2021 | EN | Official Journal of the European Union | C 21/2 |
| --- | --- | --- | --- |

20.1.2021

EN

Official Journal of the European Union

C 21/2

---

Non-opposition to a notified concentration

(Case M.10021 — Netcompany/Copenhagen Airports/SMARTER AIRPORTS JV)

(Text with EEA relevance)

(2021/C 21/02)

On 14 January 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10021. EUR-Lex is the on-line access to European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10021. EUR-Lex is the on-line access to European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
<PAGE>

                      AMENDMENT NO. 4 (THE "AMENDMENT") TO
                EMPLOYMENT AGREEMENT BETWEEN GEORGE W. BLANK AND 
             UNIVISION TELEVISION GROUP, INC., WHICH WAS ASSIGNED TO 
                   UNIVISION COMMUNICATIONS INC. ("UNIVISION")
               (AS PREVIOUSLY AMENDED, THE "EMPLOYMENT AGREEMENT") 

                                January 1, 1999

To:  Mr. George W. Blank
     c/o Univision Communications Inc.

Dear George:

     Your Employment Agreement will expire on December 31, 2000 (the "Term"). 
Univision desires to extend the Term for an additional one year period.  You 
and we hereby agree to amend the Employment Agreement as follows:

     1.  TERM.  The Term is hereby extended for an additional one year 
period.  The Employment Agreement shall expire on December 31, 2001, unless 
earlier terminated in accordance with the terms set forth in the Employment 
Agreement.

     2.  SALARY.  Your annual Base Salary rate shall be: Five Hundred Fifty 
Thousand Dollars ($550,000) for calendar year 1999;  Five Hundred Fifty 
Thousand Dollars ($550,000) for calendar year 2000; and Six Hundred Thousand 
Dollars ($600,000) for calendar year 2001. 

     3.  OTHER.  Except as provided in this Amendment, all other terms and 
conditions set forth in the Employment Agreement shall remain in full force 
and effect, and the parties hereby ratify and confirm the Employment 
Agreement, as amended hereby.

     4.  EFFECTIVE DATE OF AMENDMENT.  Upon its execution by you and 
Univision, this Amendment shall become effective as of the date first written 
above.

     5.  EXCLUSIVITY.  During the Term, you shall not directly or indirectly 
enter into any discussions or negotiations with anyone other than Univision 
for the performance of services by you after the expiration of the Term.  You 
will negotiate in good faith exclusively with Univision if Univision elects 
to seek an extension or renewal of your Employment Agreement prior to the 
expiration of the Term.

     Please indicate your agreement to this Amendment to the Employment 
Agreement by signing in the space provided below.

                                       UNIVISION COMMUNICATIONS INC.

                                       By: /s/ Robert V. Cahill
                                          --------------------------
                                           Robert V. Cahill
                                           Vice President

I have read the preceding Amendment and agree to its terms and conditions:


/s/ George W. Blank
---------------------
George W. Blank
[Federal Register Volume 86, Number 178 (Friday, September 17, 2021)]
[Notices]
[Page 51886]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20059]


-----------------------------------------------------------------------

EXPORT-IMPORT BANK

[Public Notice: 2021-6028]


Agency Information Collection Activities: Comment Request

AGENCY: Export-Import Bank of the United States.

ACTION: Submission for OMB review and comments request.

-----------------------------------------------------------------------

SUMMARY: The Export-Import Bank of the United States (EXIM), as part of 
its continuing effort to reduce paperwork and respondent burden, 
invites the general public and other Federal Agencies to comment on the 
proposed information collection, as required by the Paperwork Reduction 
Act of 1995.

DATES: Comments must be received on or before November 16, 2021 to be 
assured of consideration.

ADDRESSES: Comments may be submitted electronically on 
WWW.REGULATIONS.GOV (EIB 95-09) or by mail to Office of Information and 
Regulatory Affairs, 725 17th Street NW, Washington, DC 20038 Attn: OMB 
3048-EIB 95-09. The form can be reviewed at https://www.exim.gov/sites/default/files/pub/pending/95-09-li.pdf

FOR FURTHER INFORMATION CONTACT: To request additional information, 
please contact Donna Schneider <a href="/cdn-cgi/l/email-protection#593d36373738772a3a31373c303d3c2b193c213034773e362f"><span class="__cf_email__" data-cfemail="690d06070708471a0a01070c000d0c1b290c110004470e061f">[email protected]</span></a>, 202-565-3612.

SUPPLEMENTARY INFORMATION: The Letter of Interest (LI) is an indication 
of Export-Import (EXIM) Bank's willingness to consider financing a 
given export transaction. EXIM uses the requested information to 
determine the applicability of the proposed export transaction and 
determines whether or not to consider financing that transaction.
    Title and Form Number: EIB 95-09 Letter of Interest Application.
    OMB Number: 3048-0005.
    Type of Review: Regular.
    Need and Use: The Letter of Interest (LI) is an indication of 
Export-Import (EXIM) Bank's willingness to consider financing a given 
export transaction. EXIM uses the requested information to determine 
the applicability of the proposed export transaction system prompts and 
determines whether or not to consider financing that transaction.
    Affected Public: This form affects entities involved in the export 
of U.S. goods and services.
    Annual Number of Respondents: 400.
    Estimated Time per Respondent: 0.75 hours.
    Annual Burden Hours: 300.
    Frequency of Reporting of Use: On occasion.
    Government Expenses:
    Reviewing Time per Year: 400.
    Average Wages per Hour: $42.50.
    Average Cost per Year: $17,000 (time * wages).
    Benefits and Overhead: 20%.
    Total Government Cost: $20,400.

Bassam Doughman,
IT Specialist.
[FR Doc. 2021-20059 Filed 9-16-21; 8:45 am]
BILLING CODE 6690-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
I 

114TH CONGRESS 

1ST SESSION H. R. 2211 

To amend the Intermodal Surface Transportation Efficiency Act of 1991 

with respect to high priority corridors on the National Highway System, 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 1, 2015 

Mr. BUTTERFIELD (for himself, Mr. JONES, Mr. MEADOWS, Mr. HOLDING, 

Mr. PRICE of North Carolina, Ms. ADAMS, Mr. RIGELL, Mr. FORBES, 

Mr. SCOTT of Virginia, Mrs. ELLMERS of North Carolina, Mr. ROUZER, 

Mr. MCHENRY, Mr. WITTMAN, Mr. WALKER, and Mr. PITTENGER) introduced the following bill; which was referred to the Committee on Transportation and Infrastructure 

A BILL 

To amend the Intermodal Surface Transportation Efficiency 

Act of 1991 with respect to high priority corridors on 

the National Highway System, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Route to Opportunity 

5 And Development Act of 2015’’ or the ‘‘ROAD Act of 

6 2015’’. 


smartinez on DSK4TPTVN1PROD with BILLS
2 

•HR 2211 IH

1 SEC. 2. HIGH PRIORITY CORRIDORS ON NATIONAL HIGH2 WAY SYSTEM. 

3 (a) IN GENERAL.—Section 1105(c) of the Intermodal 

4 Surface Transportation Efficiency Act of 1991 is amended 

5 by striking paragraph (13) and inserting the following: 

6 ‘‘(13) Raleigh-Norfolk Corridor from Raleigh, 

7 North Carolina, through Rocky Mount, Williamston, 

8 and Elizabeth City, North Carolina, to Norfolk, Vir9 ginia.’’. 

10 (b) INCLUSION OF CERTAIN ROUTE SEGMENTS ON

11 INTERSTATE SYSTEM.—Section 1105(e)(5)(A) of the 

12 Intermodal Surface Transportation Efficiency Act of 1991 

13 is amended by inserting ‘‘subsection (c)(13),’’ after ‘‘sub14 section (c)(9),’’. 

Æ 


smartinez on DSK4TPTVN1PROD with BILLS
Skip to main content

Privacy Policy•Site map

# Chief Special Master Brian H. Corcoran

On behalf of the seven other special masters and staff attorneys, law clerks, and administrative staff who make up the Office of Special Masters, welcome! The Vaccine Program, as it is colloquially known, came into existence more than 30 years ago after an Act of Congress, and seeks to provide an expedited and fair means of adjudicating claims that a vaccine has caused an injury. Like the Court of Federal Claims itself, we at “OSM” are always mindful of our role as a tribunal that exists to permit citizens to bring claims against the United States. In the effort to ensure that all Vaccine Act claims receive fair consideration, we ultimately seek to serve the petitioners who bring these claims.    Consistent with our mission and the overarching purpose of the legislation that brought OSM into being, we have set forth guidelines and other practice information on this website for use to all Program petitioners, whether represented by counsel or pro se. We hope you find the enclosed information of value as you litigate your claim.

Howard T. Markey National Courts Building • 717 Madison Place, NW, Washington, DC 20439 • 202-357-6400